SI-BONE (NASDAQ:SIBN) Sets New 12-Month High – What’s Next?

SI-BONE, Inc. (NASDAQ:SIBN) hit a new 52-week high during trading on Monday . The stock traded as high as $19.35 and last traded at $18.85, with a volume of 110178 shares traded. The stock had previously closed at $18.49.

Analyst Ratings Changes

Several equities research analysts have commented on SIBN shares. Cantor Fitzgerald restated an “overweight” rating and set a $25.00 target price on shares of SI-BONE in a research report on Tuesday, May 6th. Needham & Company LLC restated a “buy” rating and set a $24.00 target price on shares of SI-BONE in a research report on Tuesday, May 6th. Finally, Truist Financial boosted their target price on shares of SI-BONE from $20.00 to $22.00 and gave the stock a “buy” rating in a research report on Tuesday, May 6th.

SI-BONE Stock Up 1.7%

The company has a debt-to-equity ratio of 0.22, a quick ratio of 7.22 and a current ratio of 8.25. The firm’s 50-day moving average is $14.53 and its 200 day moving average is $14.83. The firm has a market capitalization of $799.80 million, a PE ratio of -20.36 and a beta of 0.82.

SI-BONE (NASDAQ:SIBN) last released its quarterly earnings data on Monday, May 5th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.09. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. The business had revenue of $47.29 million for the quarter, compared to analyst estimates of $45.13 million. As a group, research analysts forecast that SI-BONE, Inc. will post -0.78 earnings per share for the current fiscal year.

Insider Activity at SI-BONE

In other news, SVP Michael A. Pisetsky sold 3,128 shares of the company’s stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $14.14, for a total transaction of $44,229.92. Following the completion of the transaction, the senior vice president now owns 244,878 shares of the company’s stock, valued at $3,462,574.92. This represents a 1.26% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Laura Francis sold 38,504 shares of the company’s stock in a transaction dated Wednesday, May 7th. The shares were sold at an average price of $17.18, for a total transaction of $661,498.72. Following the transaction, the chief executive officer now directly owns 302,958 shares of the company’s stock, valued at approximately $5,204,818.44. This represents a 11.28% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 50,216 shares of company stock valued at $841,138. 4.00% of the stock is owned by insiders.

Hedge Funds Weigh In On SI-BONE

Institutional investors and hedge funds have recently bought and sold shares of the stock. ANTIPODES PARTNERS Ltd purchased a new position in shares of SI-BONE during the 1st quarter valued at approximately $34,000. Virtus Fund Advisers LLC purchased a new position in shares of SI-BONE during the 4th quarter valued at approximately $40,000. Mainstream Capital Management LLC purchased a new position in shares of SI-BONE during the 4th quarter valued at approximately $53,000. GAMMA Investing LLC boosted its stake in shares of SI-BONE by 20,352.6% during the 1st quarter. GAMMA Investing LLC now owns 3,886 shares of the company’s stock valued at $55,000 after buying an additional 3,867 shares during the last quarter. Finally, R Squared Ltd purchased a new position in shares of SI-BONE during the 4th quarter valued at approximately $73,000. Hedge funds and other institutional investors own 98.11% of the company’s stock.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.